Theravance Biopharma (TBPH) Misses Q4 EPS by 31c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
Needham & Company Reiterates Buy on Theravance Biopharma (TBPH) Following Conference Call
February 28, 2017 7:07 AM ESTNeedham & Company reiterated a Buy rating and $40.00 price target on Theravance Biopharma (NASDAQ: TBPH) following the company's 4Q conference call.
Analyst Alan Carr commented, "Theravance mgmt hosted a 4Q16 conference call late yesterday to provide a corporate update. We note several expected... More
